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Abstract
Background: Human herpesvirus 8 (HHV-8), the aetiological agent of Kaposi’s sarcoma (KS), multicentric
Castleman’s disease (MCD), and primary effusion lymphoma (PEL) is rare in Australia, but endemic in Sub-Saharan
Africa, parts of South-east Asia and Oceania. While the treatment of external KS lesions can be monitored by clinical
observation, the internal lesions of KS, MCD and PEL require extensive and expensive internal imaging, or autopsy.
In patients with MCD and PEL, if HHV-8 viraemia is not reduced quickly, ~50% die within 24 months. HHV-8 qPCR is
a valuable tool for monitoring HHV-8 viraemia, but is not available in many parts of the world, including those with
high prevalence of KS and HHV-8.
Methods: A new molecular facility with stringent three-phase workflow was established, adhering to NPAAC and
CLSI guidelines. Three fully validated quantitative assays were developed: two for detection and quantification of
HHV-8; one for GAPDH, necessary for normalisation of viral loads in tissue and peripheral blood.
Results: The HHV-8 ORF73 and ORF26 qPCR assays were 100% specific. All qPCR assays, displayed a broad dynamic
range (102 to 1010 copies/μL TE Buffer) with a limit of detection of 4.85x103, 5.61x102, and 2.59x102 copies/μL TE
Buffer and a limit of quantification of 4.85x103, 3.01x102, and 1.38x102 copies/μL TE Buffer for HHV-8 ORF73, HHV-8
ORF26, and GAPDH respectively.
The assays were tested on a panel of 35 KS biopsies from Queensland. All were HHV-8 qPCR positive with average
viral load of 2.96x105 HHV-8 copies/μL DNA extract (range: 4.37x103 to 1.47x106 copies/μL DNA extract): When
normalised these equate to an average viral load of 2.44x104 HHV-8 copies/103 cells (range: 2.20x102 to 7.38x105
HHV-8 copies/103 cells).
Conclusions: These are the first fully optimised, validated and MIQE compliant HHV-8 qPCR assays established in
Australia. They worked well for qualitative detection of HHV-8 in archival tissue, and are well-suited for quantitative
detection in whole blood. They are now available for research, for clinical diagnosis of HHV-8 infection, and for
monitoring treatment efficacy.
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Background
Human herpesvirus 8 (HHV-8), the aetiological agent of
Kaposi’s sarcoma (KS), an AIDS-defining condition, multi-
centric Castleman’s disease (MCD) and primary effusion
lymphoma (PEL) has been extensively characterized world-
wide, but largely overlooked in Australia as the introduc-
tion of antiretroviral therapy in 1995–96 greatly reduced
the incidence of KS. Australian researchers have looked
briefly at the risk factors associated with the sexual trans-
mission of HHV-8 [1,2], at detection methods [3,4], and at
the genotyping of a few HHV-8 isolates [5]. Despite the
low prevalence of HHV-8 associated disease in Australia,
since 2007, 25 new HHV-8 PCR positive patients have
been identified in Queensland, including one child aged
just 3 years. In 2011, the first case of KS for 10 years
was recognised at the Gold Coast Sexual Health Clinic,
and a further eight cases of HHV-8 disease were
also recognised clinically in the Brisbane area suggest-
ing the possible re-emergence of HHV-8-related dis-
eases and/or increased clinical recognition and testing.
In Australia, most major anatomical pathology labora-
tories perform HHV-8 immunohistochemistry, but vali-
dated molecular assays are uncommon. HHV-8 nested
PCR is performed at PathWest Laboratory Medicine,
QEII Hospital, in Perth, Western Australia (the referral
laboratory for Queensland Health), while real-time PCR
(rtPCR) is performed at the Victorian Infectious Dis-
eases Reference Laboratory (VIDRL) in Melbourne,
Victoria and the South Eastern Area Laboratory Ser-
vices (SEALS), Prince of Wales Hospital in Sydney, New
South Wales. None of these laboratories perform quan-
titative PCR (qPCR) to monitor viral loads and treat-
ment efficacy: This is of concern because, while the
treatment of superficial KS can be monitored by clinical
observation, both MCD and PEL require more extensive
and expensive internal imaging, notably with computed
axial tomography (CAT), magnetic resonance imaging
(MRI) or positron emission tomography (PET) scans.
As the first research laboratory in Australia specialising
in the detection and characterisation of HHV-8, our first
objective was to establish fully validated HHV-8 qPCR
assays to aid in the cost-effective and timely diagnosis of
HHV-8 associated diseases, and to accurately monitor
treatment regimes and save costs of other complex moni-
toring methods. Even with the high sensitivity of PCR, most
asymptomatic patients are HHV-8 negative in this test,
making PCR an ideal technique to monitor current infec-
tions [6-8]. This report provides details to assist with over-
coming many of the challenges associated with establishing
a new quantitative assay including: laboratory establish-
ment, choice of positive and negative controls, and assay
optimisation and validation for HHV-8 ORF73, HHV-8
ORF26, and the human reference gene glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) qPCR. These assays
were used in an attempt to quantify HHV-8 in lesional bi-
opsies but, due to issues with normalisation, are better sui-
ted for viral detection and monitoring of treatment by
detecting and quantifying HHV-8 viraemia in peripheral
blood mononuclear cells (PBMC).
Methods
Body cavity-based lymphoma (BCBL)-1 cell line
harbouring latent HHV-8
BCBL-1 cells, an HHV-8 positive EBV negative cell line,
were seeded at 3-5x105 cells/mL (counted using trypan
blue), and cultured in GIBCOW RPMI-1640 supplemented
with 2 mM GlutaMAX™-I and 25 mM HEPES (Life Tech-
nologies™, Australia), as well as 10% HIA-FBS, 55 μM 2-
mecaptoethanol, 1 mM sodium pyruvate, and 100 mM
penicillin and streptomycin at 37°C in 5% CO2 in a hu-
midified atmosphere, and passaged 50% every 3–4 days.
Cell concentrations were maintained between 3x105
cells/mL and 1x106 cells/mL. Cell stocks were kept fro-
zen in liquid nitrogen in 10% DMSO and 90% HIA-
FBS, and were Mycoplasma free as determined by the
PCR Mycoplasma Test Kit (AppliChem, USA). Viral
and human genomic DNA were extracted from 100 μL
of cultured cells suspension diluted 1:1 with PBS using
the DNeasy Blood and Tissue Kit (Qiagen, Australia)
following the manufacturer’s instructions, with a pro-
teinase K digestion performed at 56°C for 10 minutes
in a heating block. All samples were eluted in 100 μL
of Buffer AE to increase the final DNA concentration.
Cloning of HHV-8 and GAPDH constructs for
qPCR standards
Amplicon containing –TA overhangs were produced
by conventional PCR performed in a 20 μL volume
containing 10X ThermoPol Reaction Buffer (New England
BioLabsW Inc., Australia), 0.4 mM deoxyribonucleotide
triphosphate (dNTP), 0.2 μM primers (GeneWorks,
Australia), 0.24 U/μL Taq DNA polymerase (New England
BioLabsW Inc., Australia) and 2 μL of nucleic acid extract
(DNeasy Blood and Tissue Kit, Qiagen, Australia). The
HHV-8 and GAPDH targets were amplified from DNA
purified from BCBL-1 cells. PCR consisted of 45 cycles of
amplification (20 seconds at 95°C; 30 seconds at 58°C, 30
seconds at 72°C), followed by a 15 minute extension step
at 72°C in an iCycler Thermal Cycler (Bio-Rad, Australia).
The entire 20 μL reaction was mixed with loading buffer
(MO BIO Laboratories, Inc., Australia) and placed in a
well of 2% w/v agarose low EEO (AppliChem, USA)
containing SYBRW Safe DNA Gel Stain (10,000X
concentrate in DMSO; Life Technologies™, Australia) in
TAE buffer (0.04 M Tris-acetate, 1 mM EDTA) and
analysed by agarose gel electrophoresis. A molecular
weight marker (DMW-100M, GeneWorks, Australia)
was added as a reference. Agarose gels were run at
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120 V for 30 minutes, visualised by exposure to blue
light (VersaDoc™ Imaging System 4000 MP, Bio-Rad,
Australia) and examined with Quality OneW V.6.3 1-D
Analysis Software (Bio-Rad, Australia). Amplicon of the
correct molecular weight was gel purified (QIAquick
Gel Extraction Kit, Qiagen, Australia) and the eluted
DNA quantified on the NanoDropW ND-1000 Spectro-
photometer (ThermoFisher Scientific, Australia).
Plasmid constructs were formed by ligating purified
PCR amplicon into pGEMW-T Easy (Promega, USA) at a
concentration of 3:1 respectively. The ligation reaction
contained 2X Quick Ligation Reaction buffer and Quick
T4 DNA Ligase (New England BioLabsW Inc., Australia)
and was performed in a 20 μL volume at 25°C for 5 min-
utes. The construct was concentrated and salts were
removed by mixing 1 mL butanol with 10 μL ligation
mixture and then centrifuging at 14,000 x g for one
minute, decanting the butanol and then drying in a
Concentrator Plus (Eppendorf South Pacific, Australia)
for 5 minutes. The construct was resuspended in 4 μL
of dH2O, mixed with 30 μL of competent DH5α
Escherichia coli, and incubated on ice for 5 minutes.
Transformation was performed in a 2 mm cuvette by
electroporation at 2.5 KV, 200 Ω, and 25 μF with the
Gene Pulser Xcell™ System (Bio-Rad, Australia). Trans-
formants were slowly shaken while incubated at 37°C
for 40 minutes in 500 μL SOC broth (2% tryptone,
0.5% yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM
MgCl2, 20 mM glucose), plated out on 2YT agar
containing 50 μg/mL ampicillin, and then grown over-
night at 37°C. The resulting constructs were named
following the convention pGEMW-T/XXXX, with the
XXXX corresponding to the HHV-8 and human
reference gene such as pGEMW-T/ORF73.
Colonies with constructs containing the gene of interest
(GOI) were selected by colony PCR screening of the
white colonies as follows: constructs were released from
bacterial cells by boiling for 2 minutes in 15 μL dH2O
and then examined by PCR using the M-13 universal
sequencing primers (USP) [50-GTAAAACGACGGCCA
GT-30] and reverse sequencing primers (RSP) [50-AT
TTCACACAGGAAACAGCTATGAC-30] [9]. PCR was
subsequently performed in a 20 μL volume containing
10X ThermoPol Reaction Buffer (New England Bio-
LabsW Inc., Australia), 0.4 mM dNTP, 0.2 μM primers
(GeneWorks, Australia), 0.24 U/μL Taq DNA polymer-
ase (New England BioLabsW Inc., Australia). Amplicon
were produced by conventional PCR consisting of 25
cycles of amplification (60 seconds at 94°C; 90 seconds
at 42°C; 60 seconds at 72°C) and then examined by
agarose gel electrophoresis as previously described.
Colonies containing the desired construct were grown
overnight at 37°C in 3 mL of 2YT broth containing
50 μg/mL ampicillin and catalogued as glycerol stocks
(800 μL culture in 200 μL 80% glycerol). Plasmid DNA
was extracted from the cultures with FastPlasmid™ Mini
Kit (5 PRIME, Australia), their concentration determined
by NanoDrop and diluted to 30 ng/μL. Constructs were
catalogued at −80°C to minimise damage from freeze/
thaw cycles, but working stocks were stored at 4°C [10].
Nucleotide sequencing was performed on both strands
of the GOI within the pGEMW-T Easy using the ABI
PRISM™ BigDye cycle sequencing kit (Perkin Elmer Ap-
plied Biosystems Division, USA) and the Applied Biosys-
tems 3130xl capillary electrophoresis genetic analyser
(Perkin Elmer Applied Biosystems Division, USA) at the
Griffith University DNA Sequencing Facility (GUDSF,
Griffith University (NATA accreditation #14814)). Nucleo-
tide sequence alignments were analysed using BioEdit
Sequence Alignment EditorW v7.0.5.2 [11] against known
sequences available in GenBank.
Optimisation and validation of quantitative PCR assays
All qPCR assays were fully optimised and validated for
the detection of HHV-8 as outlined by the Australian
National Pathology Accreditation Advisory Council
(NPAAC), Clinical and Laboratory Standards Institute
(CLSI), [formerly known as the National Committee for
Clinical Laboratory Standards (NCCLS)] and by the
Minimum Information for Publication of Quantitative
Real-Time PCR Experiments (MIQE) Guidelines, using
both cloned constructs and DNA extracted from BCBL-1
cells as the reference material [10,12-14]. The optimal
primer annealing temperature (TM) was determined on
BCBL-1 DNA extracts in duplicate with a temperature
gradient from 55.0°C to 63.0°C on an iQ5 Real-Time
PCR Detection System (Bio-Rad, Australia) using the
QuantiFast SYBR Green PCR Kit (Qiagen, Australia).
The primer concentration was determined in duplicate
using a primer matrix on both sense and anti-sense
primers so that the final concentration of the primers
in the reaction mixture are tested from 50 nM to 900 nM
[15,16]. The concentrations of the dual-labelled hydrolysis
probes were determined by testing a range between 25
nM and 300 nM. The probes were tested for integrity by
running negative controls of just water and probe at low
and high probe concentrations. The optimal TM, primer
concentration, and dual-labelled hydrolysis probe concen-
trations were determined by the amplification curve with
the best shape and lowest cycle of quantification (Cq).
The accuracy, imprecision, PCR efficiency, linearity,
measurable range, and repeatability, of the qPCR assays
were validated using calibration curves [10-fold serial
dilutions of the cloned constructs in TE Buffer (prepared
in-house: 10 mM Tris–HCl, 1 mM EDTA, pH 8.0)]. Cali-
bration curves were prepared fresh and examined in trip-
licate by qPCR on a Rotor-Gene Q (Qiagen, Australia).
The actual copy number, determined by qPCR (y-axis),
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was compared to the calculated copy number (x-axis)
graphically on Microsoft Excel with the standard devia-
tions shown in vertical error bars and examined by linear
regression analysis for linearity (R2), slope, intercept, and
standard deviation of the residuals [17,18]. The calculated
copy number was determined from the plasmid con-
centration determined via NanoDrop with the following
formulae:
1. Molecular Weight (MW) (plasmid) in g/mol = plasmid
length (bp) x 660 Da
2. Plasmid (copies/g) =Avogadro’s Number (6.02x1023)/
MW(plasmid)
3. [Plasmid] in mol/L= [plasmid] as per NanoDrop (g/L)
x MW (plasmid)
4. Plasmid (copies/μL) = [plasmid] mol/μL x MW
(plasmid) x Plasmid (copies/g)
The calibration curve was rejected if the qPCR effi-
ciency was outside the range of 95-105% (5% variance
from 100%) and linearity (R2) was <0.9800. The measur-
able range of detection was determined by the linear
region of the standard curve. The repeatability of the
assay was measured by running the standard curve in
triplicate over a 20 day period and comparing the copy
numbers. The analytical sensitivity, determined as the
limit of detection (LOD), and the limit of quantification
(LOQ), were determined from a calibration curve serially
diluted 2-fold. These calibration curves were produced in
triplicate with the quantitative standard of highest concen-
tration diluted from the quantitative standard of the
calibration curve serially diluted 10-fold, which was 10-
fold greater than the minimum detectible dilution. Each
standard was examined three times per day for eight
days [19]. The LOD was determined at the 95% confidence
interval (CI) as being the point where no less than 23/24
samples were positive, whereas the LOQ was determined
as the lowest concentration where the actual and cal-
culated concentrations were nearly identical [19,20].
Since this project was performed on a single PCR
machine by one operator, the robustness of the assay,
although desired [21], could not be determined. Add-
itionally, it would be ideal to include a comparative
evaluation of this method against reference methods
[10], but no such method is available in Australia.
The specificity of the HHV-8 qPCR assays were deter-
mined by running the assays against a panel of all HHV
and were deemed specific if the assay only amplified the
HHV-8 sample.
Quantitative PCR assays
qPCR assays were designed to amplify a 142 bp and a
234 bp fragment of the HHV-8 ORF73 and ORF26 re-
spectively as well as a 104 bp fragment of GAPDH from
previously published primer and dual-labelled hydrolysis
probe sequences (Table 1) [6,22,23]. qPCR assays were
set up manually in 0.1 mL strip tubes (Qiagen, Australia;
Cat#:981103) in a 20 μL volume using the QuantiFast™
Probe PCR+ROX Vial Kit (Qiagen, Australia) (contain-
ing HotStarTaqW Plus DNA Polymerase, dNTP mix, and
QuantiFast™ PCR buffer), 0.2 μM primers, 0.1 mM dual-
labelled hydrolysis probe (Purity: HPLC; GeneWorks,
Australia), and 2 μL of nucleic acid extract. The qPCR
reaction was performed on a Rotor-Gene Q starting with
a five minute polymerase activation step at 95°C, fol-
lowed by 45 cycles of amplification (5 seconds denatur-
ation at 95°C; 30 seconds annealing/extension at 58°C).
qPCR results were reported in “copies/μL TE Buffer” for
the calibration curves and “copies/μL DNA extract” for
the clinical isolates. For clinical samples the average
Table 1 Primers and probes used for HHV-8 and GAPDH qPCR assays





Quantitative PCR Assays for HHV-8
HHV-8 ORF73 HHV8_73_01.1 GGTGATGTTCTGAGTACATAGCGG 124,326 - 124,349 142 bp Lallemand et al., 2000
HHV8_73_02.1 CCGAGGACGAAATGGAAGTG 124,467 - 124,448
HHV8_73_Pb1 FAM-ACAAATTGCCAGTAGCCCACCAGGAGA-BHQ1ξ 124,421 - 124,395
HHV-8 ORF26 HHV8_26_01.1 AGCCGAAAGGATTCCACCATT 47,287 - 47,304 234 bp Hammock et al., 2005
HHV8_26_02.1 TCCGTGTTGTCTACGTCCAGA 47,519 - 47,499
HHV8_26_Pb.3 FAM-TGCAGCAGYTGTTGGTGTACCACAT-BHQ1ξ 47,378 - 47,402
Quantitative PCR Assays for Normalisation to Cell Counts
GAPDH GAPDH_01.1 GCTCCCTCTTTCTTTGCAGCAAT 7.800 - 7,822 104 bp Asahi-Ozaki et al., 2006
GAPDH_02.1 TACCATGAGTCCTTCCACGATAC 7,903 - 7,881
GAPDH_Pb1 FAM-TCCTGCACCACCAACTGCTTAGCACC-BHQ1ξ 7.826 - 7,851
*Nucleotide position was determined from the reference sequences [GenBank:NC_003409] for HHV-8 and [GenBank:NG_007073.2] for GAPDH.
ξProbes had 50 terminus labeled with a FAM (6-carboxy-fluorescein) fluorophore and 30 terminus labeled with BHQ-1 (Black Hole QuencherW).
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viral loads were determined from both the HHV-8
ORF73 and HHV-8 ORF26 qPCR assays and then nor-
malized to cell copy number, based on GAPDH results
(there are two copies of GAPDH/cell) and then reported
as HHV-8 copies/103 cells.
Controls and sample population
Analytical positive controls, and a range of negative controls
(analytical, no-template control (NTC) and clinically
negative tissues) were included on each PCR run to ensure
accuracy of results. BCBL-1 extracts at a concentration
~104 (10-fold higher than the assay LOD) and a 10-fold
standard curve run in singular were included in each run
to ensure PCR efficiency, linearity and that Cq values were
consistent between runs [10]. Negative controls on each
run included one sample from an HHV-8 negative oral
squamous cell carcinoma biopsy and two to three NTC
samples per run, and positioned at the front, middle and
end of each sample set [10]. A PCR run was discarded due
to inaccuracy if any of the following criteria occurred:
(i) PCR efficiency differed by 5% of the validated efficiency,
(ii) the Cq value of the positive control differed by more
than 1, (ii) any of the negative controls were positive so
that a definite sample concentration could be determined,
or if (iv) the standard curve was not linear (R2 <0.98000).
The assays were tested on an opportunistic collection
of KS archival lesions from various Queensland hospi-
tals retrospectively following ethical clearance (Griffith
University Human Research Ethics Committee (HREC)
(DOH/05/07/HREC), RBWH HREC (#2007/089), PAH
HREC (#2007/117), Townsville Hospital HREC (#39/07),
Gold Coast Hospital HREC (#200750), the Director-
General of Queensland Health (BR033835, 000784–3),
and Clinical and Statewide Services (#128)). The sample
population consisted of 35 biopsies of KS lesions from 24
patients presenting between 2004 and 2011: Eight biopsies
were from five HIV-negative patients (males:females 3:2)
with a mean age of 83.05 years (range: 78.94-88.60 years)
while 39 biopsies were from 31 HIV-positive males with a
mean age of 43.76 years (range: 28.16-66.28 years).
All clinical samples were examined by both HHV-8
qPCR assays, to determine the viral load with accuracy,
and to avoid the risk of false positives and negatives
[10,24]. If a sample yielded a negative result it was re-
examined with GAPDH to examine for inhibition, to
determine that adequate DNA was in the sample and to
verify that DNA had been extracted [10]. If a sample
yielded a positive result but the concentration was below
the LOD, it was repeated. If the repeated test showed
the sample was negative or yielded a second positive
result that was below the LOD, it was labelled as “not
detected”. If a sample was strongly positive by one of the
HHV-8 qPCR assays, but negative in the other assay the
sample was repeated in triplicate with the other assay. If
the repeat testing showed that the sample was repeatedly
negative in only one of the assays then it was recorded,
accordingly: e.g. HHV-8 ORF73 positive, HHV-8 ORF26
negative.
Results and discussion
Establishing an entirely new molecular laboratory is dif-
ficult, complex and time consuming: especially for work
with viruses that are rare in a particular geographical
area. Whether designed for research only or for clinical
diagnostics, in order to produce quality results a mo-
lecular laboratory must have stringent workflows based
on the NPAAC guidelines [10].
PCR contamination was minimized by implemen-
ting basic laboratory practices, chemical barriers, strict
sterilization practices, and a strict unidirectional PCR
workflow with three physically separate areas for: prep-
aration of reagents; DNA extraction and template add-
ing; and PCR amplification and post-PCR manipulations
[10,25-27]. However, due to space constraints, DNA
extraction was performed on a bench in the main
laboratory with template added to the PCR reaction
mixture in a Top-safe 1.2 biological safety cabinet class
II (BSCII) (Bio-Cabinets Australia Pty, Australia). Each
area contained its own dedicated equipment, reagents
and personal protective equipment [10]. As rtPCR was
performed as a sealed system, amplification was also
performed in the main laboratory with the tubes only
opened in the contained post-amplification area [10].
Carryover contamination was prevented by the strict
implementation of the unidirectional flow from pre-
amplification to post-amplification areas, with only
sealed tubes and racks travelling down the workflow
[10]. If anything needed to be re-used and go against the
unidirectional flow, such as PCR racks or bottles, they
were decontaminated overnight in a 1:100 dilution of
TrigeneW Advance (MediChem International Ltd, UK)
before returning to the pre-amplification area [10].
Cross-contamination was prevented from all DNA
extractions and template handling by wiping down the
laboratory bench and BSCII with a 1:20 dilution of
TrigeneW Advance followed by UV radiation for 20
minutes. TrigeneW Advance was used as a spray at
1:20 and 1:100 to soak used racks overnight due to its
cost effectiveness and ability to degrade DNA.
All molecular assays require clinical and analytical, posi-
tive and negative controls. Obtaining positive control sam-
ples requires formal ethical clearance which can take
many months. The usefulness of three types of molecular
analytical positive controls were therefore reviewed: the
uni-control method, synthetic controls (oligonucleotides
and/or plasmids), and plasmids (imported or in-house)
cloned from clinical isolates/cell lines (Table 2). Both the
uni-control method [28] and the production of synthetic
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Table 2 Advantages and disadvantages of three types of molecular analytical positive controls
Positive control Advantages Disadvantages Reference
Uni-Control Method • Can be used in the absence of wild-type control material • Qualitative only not quantitative Whiley et al., 2010
• Reduced contamination • Cannot be used for low viral loads
• DNA and RNA compatible • Greater risk of primer dimer formation
• Quick and simple method • Interim solution until wild-type material is available
• Does not account for sequence variation in clinical material
Synthetic Controls • DNA and RNA compatible • Synthetic oligonucleotides must be less than 200 bp Smith et al., 2006
(Oligonucleotides and/or Plasmids) • Reduced contamination (does not require cloning) • Can be expensive if target is large
• Production of a synthetic oligonucleotide and clone into a plasmid • Target sequence must be known
• No possibility of producing false-positives • Requires two separate control reactions (primer and probe)
• Can be used for rtPCR and conventional PCR
Cloned Plasmids Imported • Pre-made available (other labs or PlasmID repository) • Requires shipping None
• Cost effective • Difficult to distinguish contamination from clinical material
• Can be quantitative and qualitative • Possible contamination
Produced “in-house” • Can be quantitative and qualitative • Requires clinical material or live virus None
• Cost effective • Requires cloning (time consuming)





















controls [29] are good options, especially for the detection
of rare or hazardous viruses, as their simplistic nature pro-
duces the desirable amplification target without the need
for infectious virus. The uni-control method is a quick
and simple procedure that attaches primer binding sites to
the ends of PCR amplicon, but it is only an interim solu-
tion until wild-type material is available, and it cannot be
used to determine viral loads or to detect low viral
loads. The production of synthetic oligonucleotides,
whole genes or viral open reading frames can be used
for quantitative PCR assays, but can be expensive.
While most primer/probe manufacturing companies
can produce synthetic oligonucleotides these cannot be
quantified, and the amplicon must be small (≤200 bp).
As neither of these methods were ideal for our assays,
nor are HHV-8 quantitative controls available within
Australia, an attempt was made to import plasmids from
international laboratories. While this can be cost effective,
after facing difficulties with the Australian Quarantine and
Inspection Service (AQIS) and several failed attempts to
clone the plasmids, we acquired an HHV-8 positive, EBV-
negative body-cavity-based lymphoma cell line BCBL-1
[30]. These are freely available from the NIH AIDS Re-
search and Reference Reagent Program, easy to propagate,
and do not require ethical clearance. However, producing
constructs via cloning has several inherent risks, especially
cross-contamination due to the high copy numbers present:
these were avoided by the strict unidirectional workflow.
All constructs were cloned from DNA purified from
BCBL-1 cells, but diluted 1:1,000 in TE Buffer to yield a
Cq between 20 and 25 for optimising primers and hy-
drolysis probes. The sequences of all pGEM-T/ORF73
[GenBank:JN613421] and pGEM-T/GAPDH [GenBank:
JN613427-JN613429] constructs were identical to the pub-
lished sequences [GenBank:NC_003409] and [GenBank:
NG_007073.2] respectively (Additional files 1 and 2). The
sequence of the pGEM-T/ORF26 construct [GenBank:
JN613422-JN613426] had two conserved mismatches in all
sequenced constructs; a C ! T mismatch within the hy-
drolysis probe binding site: this required the probe se-
quence to be modified so that a pyrimidine (Y) would bind
to both possible nucleotides (Additional file 3). The second
mismatch was irrelevant. Using these constructs on a
gradient block revealed the optimal TM to be 58.0°C for
the HHV-8 ORF73 and HHV-8 ORF26 rtPCR assays.
The GAPDH rtPCR assay had two optimal TM, 58.0°C
and 62.0°C: the lower temperature was used so that all
three assays could be performed simultaneously. Using
a primer concentration matrix and hydrolysis probe
dilutions, the optimal concentrations were determined
to be 200 nM of both sense and anti-sense primers and
100 nM of hydrolysis probe (Table 3).
Analytical specificity was tested in triplicate on a panel
of DNA from all eight HHV. DNA was extracted from
separate cultures of Vero cells infected with HSV-1 and
HSV-2, cells carrying VZV, lymphoblastoid cell lines
carrying EBV, SupT1 cells carrying HHV-7, and BCBL-1
carrying HHV-8. HCMV DNA was extracted from pla-
cental tissue known to be HCMV positive, and HHV-6
DNA was obtained from viral stocks. For all viruses,
except HHV-8, the HHV-8 rtPCR assays yielded a nega-
tive result when examined via rtPCR and agarose gel
electrophoresis, thus equating to an analytical specificity
of 100% (Figure 1). This is unsurprising, considering the
specificity of PCR and that all HHV-8 primer sequences
were HHV-8 specific when analysed with NCBI’s
nucleotide-nucleotide basic local alignment search tool
(BLASTn). GAPDH amplified most samples of the
specificity panel due the virion being propagated from
human cell lines, except the HHV-6 sample for which
the agarose gel image showed possible primer-dimer
formation.
Calibration curves produced a linear relationship for
all qPCR assays from 1010 down to 102 copies/μL TE
Buffer. Both HHV-8 and the GAPDH qPCR assays pro-
duced nearly perfect efficiency and linearity (R2) with
Table 3 Optimised conditions and PCR dynamics
Assay HHV-8 ORF73 HHV-8 ORF26 GAPDH
Primer TM (°C) 58.0 58.0 58.0
[Primer] 200 nM, both primers 200 nM, both primers 200 nM, both primers
[Probe] 100 nM 100 nM 100 nM
Slope 0.96842± 0.02787 0.97243± 0.03028 0.99701± 0.02886
Intercept 0.27100± 0.20289 0.21521± 0.19569 0.02605± 0.19293
Linearity (R2) 0.99424 0.99230 0.99334
SD of Residuals 0.21584 0.27500 0.26213
Efficiency (%) 99.42 100.4 99.26
Linear Range 4.85E+03 to 6.34E+10 1.52E+02 to 1.95E+10 1.38E+02 to 3.44E+10
LOD 4.85E+03± 3.02E+03 5.61E+02± 5.46E+02 2.59E+02± 2.48E+02
LOQ 4.85E+03± 3.02E+03 3.01E+02± 2.43E+02 1.38E+02± 1.17E+02








Figure 1 Specificity of the HHV-8 ORF73 and ORF26 qPCR Assays. Amplification curves (A) and agarose gel electrophoresis images (B) of the
HHV-8 ORF73 (1) and ORF26 (2) assays tested against a panel of all eight HHV. The GAPDH PCR assay (B.3) was used as a DNA control as all
samples were prepared from cell lines, except for HHV-6 (lane 6). Various primer sets were used to test HHV-1 to −8 (lanes 1 to 8 respectively).
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Figure 2 Amplification and calibration curves. Amplification and calibration curves used to determine the linear range and efficiency from a
10-fold serial dilution of cloned constructs.
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values of 99.40% and 0.99424 for the HHV-8 ORF73
qPCR assay, 100.40% and 0.99230 for the HHV-8 ORF26
qPCR assay, and 99.26% and 0.99334 for the GAPDH
qPCR assay (Figure 2; Table 3). Calibration curves with
2-fold serial dilutions displayed near perfect replicates
from 6.43x104 to 8.04x103 copies/μL TE Buffer (average
coefficient of variation (CV) = 0.4088) and from 8.60x103
to 1.07x103 copies/μL TE Buffer for the HHV-8 ORF73
and GAPDH assays respectively (Figure 3). The LOD
and LOQ of the HHV-8 ORF73 qPCR assay were
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Figure 3 Assay sensitivity. Calibration curves using a ½-serial dilution of cloned constructs to determine the limit of detection and limit of
quantification of the HHV-8 ORF73, HHV-8 ORF26, and GAPDH qPCR assays.
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equivalent at 4.85x103 ± 3.02x103 copies/μL TE Buffer
(Cq = 37.44 ± 1.05) whereas for the GAPDH qPCR assay
the LOD was 2.59x102 ± 2.48x102 copies/μL TE Buffer
(Cq = 37.25 ± 2.16) but the LOQ was 1.38x102 ± 1.17x102
copies/μL TE Buffer (Cq = 38.52 ± 2.70) (Table 3). The
sensitivity (LOD and LOQ) of the HHV-8 ORF26 assay
was 10-fold greater than the HHV-8 ORF73 qPCR assay
but the CV was much higher (CV= 0.7740) with LOD of
5.61x102 ± 5.46x102 copies/μL TE Buffer (Cq = 35.51 ±
1.54) and LOQ of 3.01x102 ± 2.43x102 copies/μL TE
Buffer (Cq = 36.78 ± 2.02) (Table 3).
Although the LOD of our HHV-8 ORF73 qPCR assay
is 10 to 100-fold greater than previously reported using
this primer set [6,22], scrutinising these previously pub-
lished data suggests that the LOD given by these authors is
not as sensitive as stated. The assay reported by Lallemand
et al. [22] displayed a linear standard curve between 106
to 101 copies, but data for linearity and efficiency were
not given: It can be assumed, however, that their assay
was not linear above 105 copies nor below 102 copies,
based on the amplification curves shown and the high
CV values reported. Using the same primer and probe
set, Asahi-Ozaki et al. [6] displayed a linear relationship
from 108 to 101 copies for both the HHV-8 ORF73 and
GAPDH assay, but close examination of their HHV-8
ORF73 amplification curves shows tight replicates
down to 102 copies: It is unlikely that the assay can
yield accurate results below this level with any degree
of accuracy. As our amplification curves appear identical
to theirs for both assays it is most likely that the sensitiv-
ities of both our assays are comparable (Figure 2). As no
HHV-8 ORF26 qPCR assay has been published, no such
comparisons can be made for this.
The primer/probe sequences of our HHV-8 ORF26
qPCR assay have been used by many laboratories
[23,31], but problems with false positives have been
reported [32]. Hammock et al. [23] perform their PCR
assays with up to 50 cycles in order to detect potentially
very low viral loads. While many claims have been made
regarding the nature of HHV-8 in lesional tissue based
on samples amplifying after many cycles (i.e. >40 cycles),
it is our experience that the LOD of the HHV-8 ORF26
assay is 5.61x102 ± 5.46x102 copies/μL TE Buffer (Cq =
35.51 ± 1.54) and thus any sample amplifying below this
threshold is likely to be a false positive: claims based on
data from large cycle numbers are not reliable. This is
critical when used clinically, especially in patients with
MCD whose disease cannot be easily monitored visually,
for if HHV-8 viraemia is not reduced quickly the patient
could be dead in 10 months [33].
In order to eliminate the risk of false positives, clinical
isolates were tested with both the HHV-8 ORF73 and
ORF26 assays [24]: these showed that all KS biopsies
(35/35) were HHV-8 positive. The average viral load was
2.96x105 HHV-8 copies/μL DNA extract (range:
4.37x103 to 1.47x106 HHV-8 copies/μL DNA extract),
and when normalised equates to an average viral load of
2.44x104 HHV-8 copies/103 cells (range: 2.20x102 to
7.38x105 HHV-8 copies/103 cells). While it was expected
that all samples would be PCR positive, because the
pathology reports stated the tissues were HHV-8 immu-
nohistochemistry positive, no conclusion can be drawn
regarding the viral loads in different stages of KS lesional
tissue. Others have claimed to do so [6,31], but it is im-
possible to normalise to the precise number of virus
infected cells in the tissue. These assays are, therefore,
best restricted to qualitative detection of virus in tissue
samples, although they can give qualitative results in
peripheral blood where accurate cell counts can be
made. Either way these assays are clearly a valuable tool
for detection of HHV-8 infection in a range of clinical
samples.
Conclusions
Two fully optimised, validated, and MIQE compliant
HHV-8 assays have been established with excellent
sensitivity, specificity and dynamics. These assays can
be normalised by cell counts based on GAPDH qPCR
results for use in PBMC. These are the first HHV-8
qPCR assays established in Australia and are now
available for both research and clinical diagnostics.
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Additional file 1: Multiple alignment of the pGEM-T/ORF73
constructs with reference, primers, and probe sequences. Multiple
alignment of pGEM-T/ORF73 construct sequence from DH5α E. coli
colony #3 (c-3) and the HHV-8 ORF73 sense (HHV8_73_01.1) and anti-
sense (HHV8_73_02.1) primers and hydrolysis probe (HHV8_73_Pb1) with
the HHV-8 ORF73 [GenBank:NC_003409] with periods indicating identical
nucleotide bases as the reference sequence.
Additional file 2: Multiple alignment of the pGEM-T/GAPDH
constructs with reference, primers, and probe sequences. Multiple
alignment of pGEM-T/GAPDH construct sequence from three DH5α E.
coli colonies (C-1 to C-3) and the HHV-8 ORF73 sense (GAPDH_01.1) and
anti-sense (GAPDH_02.1) primers and hydrolysis probe (GAPDH_Pb1)
with the reference sequence [GenBank:NG_007073.2] with periods
indicating identical nucleotide bases as the reference sequence.
Additional file 3: Multiple alignment of the pGEM-T/ORF26
constructs with reference, primers, and probe sequences. Multiple
alignment of pGEM-T/ORF26 construct sequence from five DH5α E. coli
colonies and the HHV-8 ORF26 sense (HHV8_26_01.1) and anti-sense
(HHV8_26_02.1) primers and hydrolysis probe (HHV8_26_Pb1.1) with the
HHV-8 ORF73 [GenBank:NC_003409] with periods indicating identical
nucleotide bases as the reference sequence.
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